

information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: On October 21, 2022, the Commission instituted this investigation based on a complaint filed by Maxell, Ltd. ("Maxell") of Kyoto, Japan. 87 FR 64110 (Oct. 21, 2022). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain smart televisions by reason of infringement of one or more of claim 4 of U.S. Patent No. 8,549,109; claims 2, 4, 5, 7, and 8 of U.S. Patent No. 8,170,394; claim 1 of U.S. Patent No. 10,958,971; and claims 1 and 21 of U.S. Patent No. 11,017,815. *Id.* The Commission's notice of investigation named VIZIO, Inc. ("VIZIO") of Irvine, California as the sole respondent. The Office of Unfair Import Investigations was not named as a party in this investigation. *Id.*

On August 25, 2023, Maxell and VIZIO jointly moved to terminate the investigation in its entirety based upon reaching a settlement agreement.

On August 30, 2023, the ALJ issued the subject ID granting the motion. The ID observed that Commission Rule 210.21(a)(2) provides that "[a]ny party may move at any time to terminate an investigation in whole or in part as to any or all respondents on the basis of settlement, a licensing or other agreement" ID at 1 (citing 19 CFR 210.21(a)(2)). The ID found that in compliance with 19 CFR 210.21(b)(1), the parties certify that "there are no other agreements, written or oral, express or implied, between the parties concerning the subject matter of the investigation." *Id.* The parties also submitted confidential and public versions of the settlement agreement. *Id.* The ID further found that "termination of this investigation by settlement will not adversely affect the public interest." *Id.* (citing 19 CFR 210.50(b)(2)). No one petitioned for review of the subject ID.

The Commission has determined not to review the subject ID. The investigation is hereby terminated in its entirety.

The Commission vote for this determination took place on September 22, 2023.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as

amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: September 25, 2023.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2023-21260 Filed 9-27-23; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[USITC SE-23-048]

Sunshine Act Meetings

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: October 12, 2023 at 9:30 a.m.

PLACE: Room 101, 500 E Street SW, Washington, DC 20436, Telephone: (202) 205-2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. *Agendas for future meetings:* none.
2. Minutes.
3. Ratification List.
4. Commission vote on Inv. No. 731-TA-891 (Fourth Review) (Foundry Coke from China). The Commission currently is scheduled to complete and file its determinations and views of the Commission on October 20, 2023.
5. *Outstanding action jackets:* none.

CONTACT PERSON FOR MORE INFORMATION: Sharon Bellamy, Supervisory Hearings and Information Officer, 202-205-2000.

The Commission is holding the meeting under the Government in the Sunshine Act, 5 U.S.C. 552(b). In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.

Issued: September 26, 2023.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2023-21534 Filed 9-26-23; 4:15 pm]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1352]

Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting a Motion To Intervene

AGENCY: International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (the "Commission") has determined not to review an initial determination ("ID") (Order No. 37) granting a motion to intervene in the above-captioned investigation.

FOR FURTHER INFORMATION CONTACT: Carl P. Bretscher, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2382. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket system ("EDIS") at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 9, 2023, based on a complaint, as supplemented, filed by Viking Therapeutics, Inc. of San Diego, California ("Viking"). 88 FR 8455-56 (Feb. 9, 2023). The complaint alleges a violation of section 337 the Tariff Act, as amended, 19 U.S.C. 1337, by way of the importation, sale for importation, or sale in the United States after importation of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. *Id.* The named respondents include Ascletris Pharma Inc. of Hangzhou, Zhejiang Province, China; Ascletris Pharmaceuticals Co. of Shaoxing, Zhejiang Province, China; Ascletris